首页 | 本学科首页   官方微博 | 高级检索  
     


Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers,Israel
Authors:Yaniv Lustig  Neta Zuckerman  Ital Nemet  Nofar Atari  Limor Kliker  Gili Regev-Yochay  Einav Sapir  Orna Mor  Sharon Alroy-Preis  Ella Mendelson  Michal Mandelboim
Affiliation:1.Central Virology Laboratory, Public Health Services, Ministry of Health and Sheba Medical Center, Tel Hashomer, Israel;2.Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;3.Sheba Medical Center, Tel Hashomer, Israel;4.Public Health Services, Ministry of Health, Jerusalem, Israel
Abstract:SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective.
Keywords:COVID-19   BNT162b2 vaccination   neutralizing   variants   B.1.617.2 (Delta)
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号